AI-Generated Filing Summaries

GCL Global Holdings Ltd received a Nasdaq deficiency notice dated March 17, 2026, indicating its ordinary shares closed below $1.00 for 30 consecutive business days from February 2 to March 16, 2026, violating Nasdaq Listing Rule 5450(a)(1). The Company has 180 calendar days until September 14, 2026, to regain compliance by achieving $1.00 closes for 10 consecutive business days, with no immediate effect on listing or trading.

GCL Global Holdings Ltd received a Nasdaq deficiency notice dated March 17, 2026, indicating its ordinary shares closed below $1.00 for 30 consecutive business days from February 2 to March 16, 2026, violating Nasdaq Listing Rule 5450(a)(1). The Company has 180 calendar days until September 14, 2026, to regain compliance by achieving $1.00 closes for 10 consecutive business days, with no immediate effect on listing or trading.

Ensysce Biosciences, Inc. filed a Certificate of Correction on March 18, 2026, with the State of Delaware to the Certificate of Designation of Series B Preferred Stock, correcting a scrivener’s error in Section 4(d)(ii) regarding Principal Market Regulation and the Exchange Cap. The full corrected text is provided in Exhibit 3.1.

Ensysce Biosciences, Inc. filed a Certificate of Correction on March 18, 2026, with the State of Delaware to the Certificate of Designation of Series B Preferred Stock, correcting a scrivener’s error in Section 4(d)(ii) regarding Principal Market Regulation and the Exchange Cap. The full corrected text is provided in Exhibit 3.1.

Ridgepost Capital, Inc. disclosed that Mark Hood notified the company of his retirement as Executive Vice President and Chief Administrative Officer effective May 31, 2026, and entered into a separation and release agreement providing a $125,000 payment and a consulting agreement through March 31, 2027 with monthly fees of $15,000. Equity and carried interest awards will continue to vest during the consulting period to support transition.

Ridgepost Capital, Inc. disclosed that Mark Hood notified the company of his retirement as Executive Vice President and Chief Administrative Officer effective May 31, 2026, and entered into a separation and release agreement providing a $125,000 payment and a consulting agreement through March 31, 2027 with monthly fees of $15,000. Equity and carried interest awards will continue to vest during the consulting period to support transition.

Digi Power X Inc. announced via press release under Item 7.01 that it plans to release its financial results for the fourth quarter and year ended December 31, 2025 after markets close on March 31, 2026, and provide an operational update. The press release is furnished as Exhibit 99.1 and not deemed filed.

On March 19, 2026, Jeff Epstein informed Okta, Inc. that he would resign from the Board of Directors, effective at the Company's 2026 annual meeting of stockholders planned for June 18, 2026. Mr. Epstein’s departure is not the result of any disagreement with the Company.

Enlivex Ltd. announced FDA clearance of its IND application for a global Phase 2b trial of Allocetra in moderate-to-severe age-related symptomatic primary knee osteoarthritis, following positive Phase 1/2a data in 134 patients showing robust, durable treatment effects. This marks the company's first regulatory approval under its dual-engine value creation model.

Aurinia Pharmaceuticals Inc. appointed Kevin Tang as CEO and principal executive officer, Ryan Cole as COO, and Michael Hearne as CFO and principal financial officer, effective March 23, 2026, following the departure of prior executives including Peter Greenleaf on March 20, 2026. Craig Johnson was appointed Lead Independent Director effective March 21, 2026.

Cheer Holding, Inc. announced fiscal year 2025 financial results, with total revenues of $148.8 million up 1.1% from $147.2 million in 2024, income from operations of $26.3 million up 2.7%, and net income attributable to shareholders of $25.6 million. Cash and equivalents reached $242.1 million, app downloads hit 550 million up 5%, signaling solid performance and AI expansion plans.

Riskified Ltd. announced the appointment of Dr. Samer Haj-Yehia to its Board of Directors and Audit Committee, effective March 19, 2026, following the resignation of Aaron Mankovski from the Board after nearly a decade of service, effective March 17, 2026. The Board now consists of eight directors, six of whom qualify as independent under NYSE listing rules.

Liberty Live Holdings, Inc. closed the privately negotiated exchange of approximately $1,116 million aggregate principal amount of its 2.375% Exchangeable Senior Debentures due 2053 (Old Debentures) for an equal amount of new debentures (New Debentures) on March 20, 2026, leaving $34 million of Old Debentures outstanding. The Company entered into an indenture with U.S. Bank Trust Company, National Association as trustee governing the New Debentures.

Kandal M Venture Limited announced financial results for the six months ended September 30, 2025, with revenue of US$7,903,629 down from US$9,523,465 year-over-year due to US import tariffs, alongside a strategic 15% equity investment in Dumaine International Ltd for US$2.5 million and appointment of Fok Yui Kwong as CEO. These disclosures highlight declining profitability amid expansion efforts.

Ryanair Holdings plc purchased 9,142 ordinary shares of €0.006 nominal value and 569,396 ordinary shares underlying American Depositary Shares for cancellation from 16 March 2026 to 20 March 2026. These purchases form part of the Company's existing share buy-back programme announced on 20 May 2025, with all shares to be cancelled and weekly announcements planned.

Ryanair Holdings plc purchased 9,142 ordinary shares of €0.006 nominal value and 569,396 ordinary shares underlying American Depositary Shares for cancellation from 16 March 2026 to 20 March 2026. These purchases form part of the Company's existing share buy-back programme announced on 20 May 2025, with all shares to be cancelled and weekly announcements planned.

Theriva Biologics, Inc. announced positive outcomes from a Type B End-of-Phase 2 meeting with the FDA on March 23, 2026, regarding the Phase 3 trial design for VCN-01 combined with gemcitabine/nab-paclitaxel for metastatic pancreatic ductal adenocarcinoma. The FDA provided general agreement on the proposed single, randomized, double-blinded trial with repeat dosing, adaptive design, and overall survival as primary endpoint, supporting a potential BLA if successful.

Abundia Global Impact Group, Inc., formerly Houston American Energy Corp., reported a net loss of $29.5 million for FY 2025 ended December 31, 2025, compared to a $3.6 million net loss in FY 2024, driven by one-time charges including a $12.4 million success fee on the Share Exchange and $3.3 million shares issued as ELOC commitment fee, alongside $10.6 million in general and administrative expenses and impairments totaling $1.5 million. Oil and gas revenue was $411 thousand from legacy assets, with no revenue from the pre-commercial Renewables segment focused on low-carbon fuels from waste plastics and biomass. Total operating expenses reached $29.2 million, yielding a $28.7 million operating loss. Other expenses included $714 thousand net, leading to basic and diluted EPS of -$1 on 32.8 million weighted average shares. Balance sheet showed $31.9 million total assets, including $4.6 million cash, $9.9 million property and equipment, and $13.0 million goodwill; liabilities $12.8 million; equity $19.0 million. Cash flow: operating use $8.1 million, investing use $3.1 million, financing provide $15.2 million, net cash increase $4.1 million. The company, post-July 2025 Share Exchange, emphasizes Renewables development at Cedar Port site but faces going concern doubts due to losses and funding needs for commercialization.

Tempest Therapeutics, Inc. entered a Securities Purchase Agreement on March 20, 2026, for a private placement issuing up to 462,964 shares or 462,963 pre-funded warrants, each with Series A and Series B warrants to purchase 925,927 shares, expecting approximately $2.0 million in gross proceeds for working capital and general corporate purposes.

Companhia Paranaense de Energia - Copel issued a notice for its Annual General Meeting and Extraordinary General Meeting on April 23, 2026, at 2 p.m., held exclusively online via Ten Meetings platform. The meetings will address review of 2025 financial statements, 2026 capital budget and dividend proposals, Supervisory Board election, management compensation, and election of a Board of Directors member.

Quantum BioPharma Ltd. announced the peer-reviewed publication of a double-blind, randomized, placebo-controlled clinical trial (NCT06505239) for unbuzzd, demonstrating statistically significant acceleration of alcohol metabolism (over 40% faster BAC reduction in 30 minutes), reduced intoxication symptoms, impairment, and hangover (67% headache reduction), with no side effects. The Company owns 19.86% of Unbuzzd Wellness Inc. (as of September 30, 2025) and receives 7% royalties on unbuzzd sales up to $250 million.

Lithium Argentina AG announced fourth quarter and full year 2025 results, with Cauchari-Olaroz producing 9,700 tonnes lithium carbonate in Q4 and 34,100 tonnes for the year at the high end of guidance, Q4 revenue of $92 million, Exar Q4 net income of $31 million, and consolidated FY net loss of $76.8 million. Provided 2026 production guidance of 35,000-40,000 tonnes and completed $130 million debt facility.

Core Scientific, Inc. entered into Amendment No. 1 to its Delayed-Draw Bridge Credit Agreement on March 18, 2026, increasing term loan commitments by $500.0 million to $1.0 billion total via JPMorgan Chase Bank, N.A., and borrowed the full incremental amount on the Closing Date. This provides additional financing for data center asset development, enhancing liquidity for infrastructure expansion.

Core Scientific, Inc. entered into Amendment No. 1 to its Delayed-Draw Bridge Credit Agreement on March 18, 2026, increasing term loan commitments by $500.0 million to $1.0 billion total via JPMorgan Chase Bank, N.A., and borrowed the full incremental amount on the Closing Date. This provides additional financing for data center asset development, enhancing liquidity for infrastructure expansion.

Core Scientific, Inc. entered into Amendment No. 1 to its Delayed-Draw Bridge Credit Agreement on March 18, 2026, increasing term loan commitments by $500.0 million to $1.0 billion total via JPMorgan Chase Bank, N.A., and borrowed the full incremental amount on the Closing Date. This provides additional financing for data center asset development, enhancing liquidity for infrastructure expansion.

Eco Wave Power's Taiwanese partner I-Ke signed a five-year land lease agreement with Suao Port in December 2025 for the Suao Port wave energy project site, enabling advancement to the next development phase. This milestone supports the company's Asia-Pacific expansion and demonstration of locally manufactured wave energy systems in new markets.

Powell Max Limited signed a non-binding Letter of Intent to acquire The Boston Solar Company, valued at $9.0 million including up to $7.0 million debt assumption, with definitive agreement expected by May 16, 2026, subject to due diligence. This supports Powell Max's diversification into solar energy amid rising U.S. energy demand.

HomesToLife Ltd (HTLM) reported strong FY 2025 results with total revenues, net of $377.9M, up 12.8% YoY from $335.1M in FY 2024, driven by a 12.0% increase in export sales to $349.6M (92.5% of total) and retail sales growth to $9.1M (2.4%). Gross profit rose 26.8% to $105.3M, with gross margin expanding to 27.9% from 24.8%, reflecting a favorable product mix shift toward higher-margin fabric sofas. Operating income surged 103.7% to $19.4M, supported by sales volume growth despite higher freight costs from Suez Canal disruptions. Net income climbed 96.6% to $16.6M, or $0.18 per basic/diluted share (up from $0.09). Balance sheet strengthened with total assets at $139.2M (up from $118.8M), equity at $27.8M, and cash at $27.3M. Operating cash flow was $13.5M, with net cash increase of $2.4M. Leather trading contributed $19.2M (5.1%). Forward-looking, management highlights integrated supply chain resilience and brand expansion amid global economic pressures.

Stran & Company, Inc. issued a press release announcing a conference call on March 26, 2026, at 10:00 A.M. Eastern Time to discuss its financial results for the 2025 fiscal year ended December 31, 2025, corporate progress, and other developments. The information is furnished as Exhibit 99.1 under Item 7.01 and is not deemed filed.

Stran & Company, Inc. issued a press release announcing a conference call on March 26, 2026, at 10:00 A.M. Eastern Time to discuss its financial results for the 2025 fiscal year ended December 31, 2025, corporate progress, and other developments. The information is furnished as Exhibit 99.1 under Item 7.01 and is not deemed filed.